Scientific and clinical expertise
Scientific and clinical expertise are the pillars of our work
Esmethadone (REL-1017) is an investigational compound. Safety and efficacy have not been established, and no regulatory authority has approved this product for any indication. Statements herein reflect interpretations of published or presented data.
Our team has been collaborating for years with leading experts in the field of neuropsychiatry, such as Maurizio Fava, Steven Stahl and Thomas Kosten. Esmethadone's peer reviewed articles are authored by leading scientists in the field.
Our scientists and clinicians have worked in top medical institutions, including, among others, Harvard University, Cornell University, the University of Texas, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, Mount Sinai Hospital, Massachusetts General Hospital.
Paolo Manfredi, MD
Chief Scientific Officer and Acting Chief Executive Officer
Paolo Manfred is a neurologist and esmethadone expert. Paolo is a co-founder of Medeor Inc. a joint venture with Cornell Center for Technology Enterprise & Commercialization (CCTEC). Medeor then merged to form Relmada Therapeutics, a publicly traded biotechnology company. Dr. Manfredi is a co-inventor of several pharmaceutical patents currently under development. REL-1017 (esmethadone), a well tolerated and safe oral, once-daily NMDA receptor antagonist is currently in Phase 3 for the adjunctive treatment of major depressive disorders. REL-P11 (MR psilocybin) has successfully completed a SAD Phase 1 study in overweight-obese subjects and in normal BMI subjects and is Phase 2 ready.
Marco Pappagallo, MD
Chief Medical Officer and Head of Safety
Marco Pappagallo is a Neurologist and Clinical Professor of Anesthesiology at Albert Einstein College of Medicine, New York. Marco is an internationally renowned researcher and lecturer with over 100 publications and a seasoned inventor of pharmaceuticals. Marco has conducted (PI) clinical trials sponsored by NIH, Glaxo, Roche, and Pfizer and has held CMO positions in several biotechnology companies, including Relmada Therapeutics. Marco is a co-inventor on the psilocybin platform, which includes REL-P11, a Phase 2-ready molecule.
